Botulinum Toxin Injections for Psychiatric Disorders: A Systematic Review of the Clinical Trial Landscape
Open Access
Abstract
Botulinum toxin type A (BONT-A) has shown promise in improving the mood-related symptoms of psychiatric disorders by targeting muscles linked to the expression of negative emotions. We conducted a systematic review of past and ongoing efficacy trials of BONT-A therapy for psychiatric disorders to identify relevant trends in the field and discuss the refinement of therapeutic techniques. A comprehensive search for published clinical trials using BONT-A injections for psychiatric disorders was performed on 4 May 2023 through OVID databases (MEDLINE, Embase, APA PsycINFO). Unpublished clinical trials were searched through the ClinicalTrials.gov and International Clinical Trial Registry Platform public registries. The risk of bias was assessed using the JBI Critical Appraisal tools for use in systematic reviews. We identified 21 studies (17 published, 4 unpublished clinical trials) involving 471 patients. The studies focused on evaluating the efficacy of BONT-A for major depressive, borderline personality, social anxiety, and bipolar disorders. BONT-A was most commonly injected into the glabellar area, with an average dose ranging between 37.75 U and 44.5 U in published studies and between 32.7 U and 41.3 U in unpublished trials. The results indicated significant symptom reductions across all the studied psychiatric conditions, with mild adverse effects. Thus, BONT-A appears to be safe and well-tolerated for psychiatric disorders of negative affectivity. However, despite the clinical focus, there was a noted shortage of biomarker-related assessments. Future studies should focus on pursuing mechanistic explorations of BONT-A effects at the neurobiological level.Keywords
This publication has 79 references indexed in Scilit:
- Effects of glabellar botulinum toxin injections on resting-state functional connectivity in borderline personality disorderEuropean Archives of Psychiatry and Clinical Neuroscience, 2023
- The safety and efficacy of botulinum toxin A on the treatment of depressionBrain and Behavior, 2021
- Botulinum Toxin: Does it have a Place in the Management of Depression?CNS Drugs, 2018
- Affective pictures processing is reflected by an increased long-distance EEG connectivityCognitive Neurodynamics, 2017
- Cortical functional connectivity is associated with the valence of affective statesBrain and Cognition, 2014
- The Voluntary Facial Action Technique: A Method to Test the Facial Feedback HypothesisJournal of Nonverbal Behavior, 2010
- Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participantsJournal of the American Academy of Dermatology, 2009
- Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial DataArchives of internal medicine (1960), 2009
- Botulinum toxin and the facial feedback hypothesis: Can looking better make you feel happier?Journal of the American Academy of Dermatology, 2008
- Botulinal neurotoxins: revival of an old killerCurrent Opinion in Pharmacology, 2005